Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study.

Authors :: DeVincenzo, John P.
Whitley, Richard J.
Mackman, Richard L.
Scaglioni-Weinlich, Cecilia
Harrison, Lisa
Farrell, Eric
McBride, Stephen
Lambkin-Williams, Robert
Jordan, Robert
Yan Xin
Ramanathan, Srini
O'Riordan, Thomas
Lewis, Sandra A.
Xiaoming Li
Toback, Seth L.
Shao-Lee Lin
Chien, Jason W.
Source :: New England Journal of Medicine. 8/21/2014, Vol. 371 Issue 8, p711-722. 12p. 1 Color Photograph, 4 Charts, 1 Graph.
Publication Year :: 2014
Abstract: The article offers information on a randomized clinical trial conducted to observe the activity of GS-5806, which is an inhibitor of respiratory syncytial virus (RSV) that leads to infant hospitalizations, morbidity and mortality. It states that the participants were divided into two groups, one received GS-5806 and other received placebo. It concludes that the treatment of infants with GS-5806 reduced the viral load of RSV.